MedTrace Logo

Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension

NCT03459716 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2021-09-10

No results posted yet for this study

Summary

Systemic sclerosis (SSc, AKA scleroderma) is an autoimmune condition characterized by endothelial damage and progressive fibrosis of the skin and internal organs. One of the leading causes of morbidity and mortality in patients with SSc is pulmonary hypertension (PH), which is estimated to occur in up to 31% of high risk SSc patients. Early detection of patients with SSc-PH may lead to improved outcomes and although there have been concerted efforts to accurately screen for SSc-PH, these patients continue to present with advanced disease and suffer from poor survival. Therefore, better methods to screen for patients with PH and, perhaps more importantly, to screen for those at risk for PH development are desperately needed. Since PH and SSc are disorders originating from the endothelium, biomarkers that reflect endothelial damage are very promising tools to identify early disease. Such potential biomarkers include endothelial microparticles, asymmetric dimethylarginine (ADMA), pentraxin-3, and soluble endoglin. No previous study has used a combination of these biomarkers to detect the presence of PH in patients with SSc, or studied the novel concept of exercise-induced changes in biomarker levels. The investigators will collect the above listed endothelial biomarkers before and after exercise, and combine these levels with exercise echocardiogram findings, and routine clinical information to derive a composite detection score for the early identification of systemic sclerosis-associated PH.

Conditions

  • Scleroderma
  • Pulmonary Hypertension

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Scleroderma Foundation

    collaborator UNKNOWN

  • Tulane University Health Sciences Center

    collaborator OTHER

  • University Medical Center-New Orleans

    collaborator UNKNOWN

  • Louisiana State University Health Sciences Center in New Orleans

    lead OTHER

Principal Investigators

  • Matthew R Lammi, MD, MSCR · LSU Health Sciences Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-10-31
Completion
2021-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03459716 on ClinicalTrials.gov